Nido Biosciences Presents Clinical Data Supporting the Continued Development of NIDO-361 in SBMA Patients at the 2023 International Kennedy’s Disease Patient Conference
NIDO-361 was generally well-tolerated when administered in Ph1 study as a single- or as multiple-oral doses in healthy subjects Observational study confirms MRI may serve as reliable endpoint for future clinical development program WATERTOWN, Mass.–(BUSINESS…